BioHarvest Sciences Inc. (NASDAQ:BHST) Short Interest Update

BioHarvest Sciences Inc. (NASDAQ:BHST) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 33,198 shares, a drop of 52.9% from the November 30th total of 70,472 shares. Based on an average daily trading volume, of 64,612 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the shares of the company are short sold. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 64,612 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 22nd. Wall Street Zen upgraded BioHarvest Sciences to a “hold” rating in a research note on Saturday, October 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.50.

BioHarvest Sciences Price Performance

NASDAQ:BHST traded down $0.28 during trading hours on Friday, hitting $5.33. 28,864 shares of the company’s stock traded hands, compared to its average volume of 59,806. BioHarvest Sciences has a 52 week low of $4.72 and a 52 week high of $12.80. The business’s fifty day simple moving average is $7.29 and its two-hundred day simple moving average is $8.02. The company has a quick ratio of 1.02, a current ratio of 1.35 and a debt-to-equity ratio of 0.30. The firm has a market cap of $87.52 million, a P/E ratio of -7.84 and a beta of 0.95.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). The firm had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.11 million. BioHarvest Sciences had a negative return on equity of 1,041.86% and a negative net margin of 36.33%. On average, research analysts anticipate that BioHarvest Sciences will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC boosted its position in BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,013 shares of the company’s stock after buying an additional 146,365 shares during the quarter. True North Advisors LLC owned approximately 1.02% of BioHarvest Sciences worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.